Glenmark Pharma said that results from a study suggests similarity between biosimilar GBR 310 and the reference product omalizumab.from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2A9cGQp
via IFTTT
Study suggests similarity between biosimilar GBR 310 and omalizumab: Glenmark
Glenmark Pharma said that results from a study suggests similarity between biosimilar GBR 310 and the reference product omalizumab.from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2A9cGQp
via IFTTT
0 comments:
Post a Comment